Venus Remedies Limited is a research-driven pharmaceutical company. The Company is a global injectable manufacturer. It manufactures products catering to critical care segments such as antimicrobial resistance, anti-cancer, Anti-infective, Neurology, Skin and Wound Care, and Pain Management. With a diverse portfolio of products, the Company is dedicated to revolutionizing patient care through its specialized therapeutic segments such as anti-infective (antibiotics), oncology, neurology, pain management, and skin & wound care. The Company operates only in one business segment: Pharmaceutical Formulation and is engaged in manufacturing and trading of medicines. Its focus therapy areas include medicine, surgery, neuro and orthopedics. The Company’s brands include Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, and others. It has three manufacturing facilities: Panchkula and Baddi in India and Werne in Germany.As of 9 Jun 2026, VENUS REMEDIES share price is ₹1,638.00. The stock opened at ₹1,696.10, compared to its previous close of ₹1,695.40. During today's trading session, VENUS REMEDIES share price moved in the range of ₹1,610.70 to ₹1,736.90, with an average price of ₹1,673.80 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,610.70 and a high of ₹1,736.90. On the performance front, VENUS REMEDIES share price has increased by 122.23% over the last six months and is up 294.28% on a year-on-year basis.
The market capitalization of VENUS REMEDIES is ₹2,188 Crs, with a P/E ratio of 21.3 and a dividend yield of 0.00%.